Signal #136345 · SEC 8-K

$ACAD SEC Filing Alert & Real-Time AI Stock Impact Analysis

Public T0 SEO entry. Full AI score & bullets unlock after 4 hours (VIP: instant).

FAQ: $ACAD filing catalyst

Why did $ACAD trigger an AI stock catalyst alert?

$ACAD triggered a Stock Catalyst AI alert on 2026-11-04 00:00:00 UTC for a SEC 8-K filing (AI Score: +6.5/10). Headline: Acadia Pharmaceuticals Reports Q3 Revenue Up 22% to $342M, Raises 2026 DAYBUE Guidance. Key points: - Total revenues rose 22% YoY to $342M, with DAYBUE sales up 39% YoY to $140M. - 2026 DAYBUE net sales guidance raised to $505M–$520M; R&D expense guidance reduced to $325M–$340M. - Q3 GAAP diluted EPS reported at $0.31 compared to $0.42 in prior-year period.

How did $ACAD stock react after the SEC filing?

After the SEC 8-K for $ACAD, observed market reaction: T0 price $21.47. Past moves do not guarantee future results.

Where can I get real-time $ACAD SEC filing alerts?

Stock Catalyst AI pushes real-time SEC 8-K alerts for $ACAD via Telegram and the VIP Web Terminal from €10/month.

$ACAD

$ACAD – Acadia Pharmaceuticals Reports Q3 Revenue Up 22% to $342M, Raises 2026 DAYBUE Guidance

ACADIA PHARMACEUTICALS INC

2026-11-04 00:00:00 UTC · SEC 8-K · All $ACAD

Unlocked archive · Analyzed in <2s at T0

Bullish AI Sentiment (+6.5 / 10)

Total revenues rose 22% YoY to $342M, with DAYBUE sales up 39% YoY to $140M.
2026 DAYBUE net sales guidance raised to $505M–$520M; R&D expense guidance reduced to $325M–$340M.
Q3 GAAP diluted EPS reported at $0.31 compared to $0.42 in prior-year period.

Unlock Live VIP Terminal & Telegram – €10/mo Original filing →